These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26268909)

  • 41. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. One year course of oral sulodexide in the management of diabetic nephropathy.
    Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M
    J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnosis, implication, prevention and treatment of microalbuminuria].
    Schmieder RE; Bramlage P
    Dtsch Med Wochenschr; 2012 Jul; 137(27):1409-16; quiz 1417-8. PubMed ID: 22736183
    [No Abstract]   [Full Text] [Related]  

  • 45. Discounting the efficacy of sulodexide in diabetic nephropathy is premature.
    Gambaro G
    Am J Kidney Dis; 2012 Jul; 60(1):169-70. PubMed ID: 22709598
    [No Abstract]   [Full Text] [Related]  

  • 46. Sulodexide for diabetic nephropathy: another one bites the dust.
    House AA; Weir MA
    Am J Kidney Dis; 2011 Nov; 58(5):692-4. PubMed ID: 22014634
    [No Abstract]   [Full Text] [Related]  

  • 47. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

  • 48. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
    Castoldi G; di Gioia CR; Bombardi C; Maestroni S; Carletti R; Steckelings UM; Dahlöf B; Unger T; Zerbini G; Stella A
    Am J Physiol Renal Physiol; 2014 Nov; 307(10):F1123-31. PubMed ID: 25186297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [INNOVATION study].
    Ogawa D; Makino H
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():451-4. PubMed ID: 21667499
    [No Abstract]   [Full Text] [Related]  

  • 51. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
    Kimura S; Inoguchi T; Yokomizo H; Maeda Y; Sonoda N; Takayanagi R
    Diabetes Obes Metab; 2012 Jul; 14(7):666-9. PubMed ID: 22268518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paricalcitol for reduction of albuminuria in diabetes.
    Kassimatis T
    Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334524
    [No Abstract]   [Full Text] [Related]  

  • 54. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Game not over for sulodexide.
    Coccheri S
    Am J Kidney Dis; 2012 Mar; 59(3):467. PubMed ID: 22340910
    [No Abstract]   [Full Text] [Related]  

  • 56. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy.
    Cucak H; Nielsen Fink L; Højgaard Pedersen M; Rosendahl A
    Int Immunopharmacol; 2015 Mar; 25(1):30-42. PubMed ID: 25598292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The Shiga Microalbuminuria Reduction Trial].
    Hiroo K; Oda T; Kushiyama T; Higashi K; Yamamoto K
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():445-50. PubMed ID: 21661182
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
    de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.
    Dawson JRD; Wadman GM; Zhang P; Tebben A; Carter PH; Gu S; Shroka T; Borrega-Roman L; Salanga CL; Handel TM; Kufareva I
    bioRxiv; 2024 Feb; ():. PubMed ID: 38014122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.